Shortage of burial shrouds as dozens more Gazans die
The 10 died in two separate incidents near aid sites belonging to the US-backed Gaza Humanitarian Foundation, in central and southern Gaza, local medics said. The United Nations says more than 1000 people have been killed trying to receive aid in the enclave since the GHF began operating in May 2025, most of them shot by Israeli forces operating near GHF sites.
"Everyone who goes there, comes back either with a bag of flour or carried back (on a wooden stretcher) as a martyr, or injured. No one comes back safe," said 40-year-old Palestinian Bilal Thari.
He was among mourners at Gaza City's Al Shifa hospital on Monday who had gathered to collect the bodies of their loved ones killed a day earlier by Israeli fire as they sought aid, according to Gaza's health officials.
At least 13 Palestinians were killed on Sunday while waiting for the arrival of UN aid trucks at the Zikim crossing on the Israeli border with the northern Gaza Strip, the officials said.
At the hospital, some bodies were wrapped in thick patterned blankets because white shrouds, which hold special significance in Islamic burials, were in short supply due to continued Israeli border restrictions and the mounting number of daily deaths, Palestinians said.
"We don't want war, we want peace, we want this misery to end. We are out on the streets, we all are hungry, we are all in bad shape, women are out there on the streets, we have nothing available for us to live a normal life like all human beings, there's no life," Thari told Reuters.
There was no immediate comment by Israel on Sunday's incident.
The Israeli military said in a statement to Reuters that it had not fired earlier on Monday in the vicinity of the aid distribution centre in the southern Gaza Strip, but it did not elaborate further.
Israel blames Hamas for the suffering in Gaza and says it is taking steps for more aid to reach its population, including pausing fighting for part of the day in some areas, air drops, and announcing protected routes for aid convoys.
Israeli Prime Minister Benjamin Netanyahu said on Monday he would convene his security cabinet this week to discuss how the military should proceed in Gaza to meet all his government's war goals, which include defeating Hamas and releasing the hostages.
Meanwhile, five more people died of starvation or malnutrition over the past 24 hours, Gaza's health ministry said on Monday. The new deaths raised the toll of those dying from hunger to 180, including 93 children, since the war began.
UN agencies have said that airdrops of food are insufficient and that Israel must let in far more aid by land and quickly ease access to it.
COGAT, the Israeli military agency that coordinates aid, said that during the past week, over 23,000 tons of humanitarian aid in 1200 trucks had entered Gaza but that hundreds had yet to be driven to aid distribution hubs by UN and other international organisations.
Israel's military later said 120 aid packages containing food had been dropped into Gaza "over the past few hours" by six different countries in collaboration with COGAT.
The Hamas-run Gaza government media office said on Sunday that more than 600 aid trucks had arrived since Israel eased restrictions in late July. However, witnesses and Hamas sources said many of those trucks have been looted.
Palestinian and UN officials said Gaza needs around 600 aid trucks to enter per day to meet the humanitarian requirements - the number Israel used to allow into Gaza before the war.
The Gaza war began when Hamas killed 1200 people and took 251 hostage in an attack on southern Israel on October 7, 2023, according to Israeli figures. Israel's offensive has since killed more than 60,000 Palestinians, according to Gaza health officials.
According to Israeli officials, 50 hostages now remain in Gaza, only 20 of whom are believed to be alive.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
22 minutes ago
- News.com.au
Health Check: Neuren says the US Rett syndrome market is a case of glass half full
Neuren's US partner Acadia reports a 14% sales boost Look out for a slew of advanced clinical trial results in early 2026 IDT Australia shares plunge up to 39% after CEO departs 'with immediate effect' Despite firming US sales of its Rett syndrome treatment Daybue, Neuren Pharmaceuticals (ASX:NEU) says two-thirds of eligible patients are yet to try the drug. Neuren's US partner Acadia Pharmaceuticals overnight reported quarterly net sales of US$96.1 million, up 14% year on year. The Nasdaq-listed Acadia says a record number of patients received a shipment, growing for the third consecutive quarter. Acadia holds the global rights to Daybue and pays royalties to Neuren, which initially developed the drug. Affecting boys, Rett syndrome is a rare neurodevelopmental disorder resulting in slow development after the ages of six to 18 months. Acadia has guided to net sales of US$380-405 million, which at the current exchange rate will generate $62-67 million of royalties for Neuren in calendar 2025. Neuren earned $14.7 million in the June quarter, up 16% year on year. By their nature, royalties are pretty much pure profit. More patients – and they're more persistent Acadia says a record 987 patients received Daybue in the quarter, up from 954 in the March quarter. Despite concerns about side effects, 50% of patients persisted after 12 months' treatment. Neuren adds that 70% of active patients have now been on therapy for 12 months or longer. This was up from 65% previously. The company says two-thirds of the 5500 to 5800 diagnosed US patients are yet to try Daybue. The FDA approved the therapy in March 2023 and Acadia expects European assent in the March 2026 quarter. Neuren shares this morning spurted as much as 8%. They've more than doubled since their mid-April trough of $8.60. Investors spoil IDT's golden jubilee Veteran contract drug maker IDT Australia's (ASX:IDT) golden jubilee has been spoiled by a savage share rout, resulting from the news that CEO Paul McDonald would depart 'with immediate effect'. The company also issued a lacklustre trading update, flagging a boost in revenue for the year to June 30, 2025, but a widening loss. A former Pfizer exec, McDonald had been in the job for almost three years. Chairman Mark Simari becomes executive chair while the company searches for a new CEO. IDT says its full-year revenue should come in at $19.9 million, a 40% increase. The company cites an increase in disbursement revenue. This derived from raw material costs and equipment charged to customers at a 'modest' margin. IDT says mainly applying to new contracts, disbursements are a 'positive lead indicator'. IDT also expects a net loss of $7.5 million, compared with a $5.4 million deficit last year. This reflects $1.2 million of bad debts from two customers defaulting on payments. Founded in 1975, IDT has had a convoluted history, including missing out on a government funded Covid vaccine plant at the last minute. These days IDT pursues gene technology, antibody drug conjugates, medical marijuana and psychedelic treatments for mental disorders. The company is in the third year of its five-year strategy, spurred by a board 'refresh' in September 2022. IDT's $30 million worth is backed by the value of the company's Boronia premises in eastern Melbourne. This hard-to-replicate is in the books at a conservative $21 million. We're on track, say drug developers Investors can look forward to a slew of company-making trial results in 2026, according to presenters at this year's Bioshares summit in Hobart. Alzheimer's disease drug developer Actinogen Medical (ASX:ACW) says it's on track to report interim results from its advanced phase IIb/III trial, by January next year. The company is enrolling 220 patients for its Xanamia trial for mild to moderate sufferers, across 15 Australian and 20 US sites. Actinogen's candidate Xanamem targets excess levels of cortisol in the brain – a novel mechanism of action. The company expects to unveil data from the first 100 patients, after 24 weeks' treatment. Final results are expected in late 2026. Stem cell developer Cynata Therapeutics (ASX:CYP) expects to release results of its phase III osteoarthritis (OA) trial between February and April next year. Cynata's mesenchymal stromal cells modulate the immune system and enable tissue repair. The OA program is the most advanced of Cynata's four trials that also cover graft-versus-host disease, diabetic foot ulcers and kidney transplants. Vitiligo is a circa US$500 million market, says Clinuvel The developer of an approved treatment for a rare sun intolerance disorder abbreviated as EPP, Clinuvel Pharmaceuticals (ASX:CUV) is advancing its proposed treatment for the more common vitiligo. The company has fully enrolled its 210 patient phase III trial, with a readout due in the June half. Affecting about 1% of the population, vitiligo is skin discolouration that results from the destruction of pigment-producing cells called melanocytes. The late Michael Jackson was a celebrity sufferer. If the drug gets US Food and Drug Administration (FDA) approval, the company estimates US$490-570 million of revenue in years one and two. Put in context, Clinuvel reported revenue of $35.6 million in the 2024 December half, up 10%. These sales derived from the company's EPP treatment, Scenesse. Doing the numbers on Imricor Broker Canaccord reckons Imricor Medical Systems (ASX:IMR) could be worth more than twice its current valuation – but faces constrained hospital budgets for the time being. In a 60-page appraisal of the cardiac ablation catheter developer, the firm estimates 120 US hospitals could be using the device within five years. Assuming 35% penetration of the ablation procedures, this equates to a $2.50 per share valuation compared with around $1.40 now. 'The big question ... is how quickly can these installs happen,' the firm says. Uniquely, Imricor's catheters are guided in real-time with magnetic resonance imaging – MRI – rather than via x-ray. The procedure is called interventional cardiac magnetic resonance cardiac ablation (ICMR CA). The company initially is focused on the US$12b arrhythmia market. Canaccord believes Imricor is still 12-18 months away from a 'material revenue ramp'. But after that it's off to the races. Imricor has an initial US target market as 120 large academic hospitals, 20 of them high volume. The firm estimates that facilities will install 190 ICMR US labs globally five years post launch. Of these, 100 will be in the US with total revenue of US$250 million. Imricor currently is undertaking a trial aimed at FDA approval for atrial flutter procedures, with a decision by the end of 2026.
SBS Australia
3 hours ago
- SBS Australia
At least 38 Palestinians killed while seeking aid in Gaza, local health officials say
At least 38 Palestinians were killed on Wednesday in the Gaza Strip while seeking aid from United Nations convoys and sites run by an Israeli-backed American contractor, according to local health officials. The Israeli military said it had fired warning shots when crowds approached its forces. Another 25 people, including several women and children, were killed in Israeli airstrikes, according to local hospitals in Gaza. The military said it only targets Hamas militants. UN-backed food security experts said last week the "worst-case scenario" of famine is playing out in Gaza, with mounting evidence of "widespread starvation, malnutrition, and disease" driving a rise in hunger-related deaths. Israel has consistently denied allegations it has fuelled a hunger crisis in Gaza, instead blaming Hamas and claiming the listed terror group has weaponised humanitarian aid to supply its fighters. A new UN report said only 1.5 per cent of Gaza's cropland is accessible and undamaged. Of the 38 Palestinians killed while seeking aid, at least 28 died in the Morag Corridor, an Israeli military zone in southern Gaza where UN convoys have been repeatedly overwhelmed by looters and desperate crowds in recent days, and where witnesses say Israeli forces have repeatedly opened fire. The Israeli military said troops fired warning shots as Palestinians advanced towards them, and that it was not aware of any casualties. Nasser Hospital, which received the bodies, said another four people were killed in the Teina area, on a route leading to a site in southern Gaza run by the Israeli-backed Gaza Humanitarian Foundation (GHF), an American contractor. The al-Awda Hospital said it received the bodies of six people killed near a GHF site in central Gaza. GHF said there were no violent incidents at or near its sites. Two of the Israeli airstrikes hit Gaza City, in the north of the territory, killing 13 people there, including six children and five women, according to the al-Ahli Hospital, which received the bodies. The Israeli military says it only targets militants and blames civilian deaths on Hamas because its militants are entrenched in heavily populated areas. UN experts say Israeli-backed aid group should be dismantled. Israel facilitated the establishment of four GHF sites in May after blocking the entry of all food, medicine and other goods for 2.5 months. Israeli and United States officials said a new system was needed to prevent Hamas from siphoning off humanitarian aid. Hamas has denied stealing aid. An internal US government analysis, conducted by a bureau within the US Agency for International Development in late June, found no evidence of systematic theft of US-funded humanitarian supplies by Hamas. Separately, the European Commission has said it has found no reports of Hamas stealing humanitarian aid in Gaza. The UN, which has delivered aid to hundreds of distribution points across Gaza throughout the war when conditions allow, has rejected the new system, saying it forces Palestinians to travel long distances and risk their lives for food, and that it allows Israel to control who gets aid, potentially using it to advance plans for further mass displacement. The UN human rights office said last week at least 1,373 Palestinians have been killed while seeking food since 27 May, mostly near GHF sites but also along UN convoy routes where trucks have been overwhelmed by crowds. It says nearly all were killed by Israeli fire. This week, a group of UN special rapporteurs and independent human rights experts called for the GHF to be disbanded, saying it is "an utterly disturbing example of how humanitarian relief can be exploited for covert military and geopolitical agendas in serious breach of international law".
Perth Now
4 hours ago
- Perth Now
Big problem with essential Aussie scheme
Health Minister Mark Butler says he is looking at recommendations to speed up medicine approvals amid pressure from lobbyists both within Australia and in the US. Medicines Australia has repeatedly highlighted that Australia lags behind comparable countries in listing new medicines on the Pharmaceutical Benefits Scheme (PBS) – a list of federally subsidised medicines. It takes an average of 466 days from when the Therapeutic Goods Administration approves a medicine to when it becomes affordable on the PBS, according to the peak body. This is much longer than in the UK and Canada, for example. The lengthy timeline has also angered the Pharmaceutical Research and Manufacturers of America (PhRMA), which has framed the PBS as a 'non-tariff trade barrier' that harms American companies in representations to the Trump administration. Lengthy PBS listing times is among PhRMA's core criticisms. Mr Butler said on Thursday he would look at Medicines Australia's recommendations to make the 'approvals system quicker'. Powerful pharmaceutical lobbyists in the US have accused Australia of 'freeloading' on the high prices paid by American consumers. Martin Ollman / NewsWire Credit: News Corp Australia 'We're getting an enormous number of new medicining coming on to the market,' he told the ABC. 'We're living through a turbocharged period of discovery bringing more and more new medicine, so making sure that we can assess them and approve them very quickly to get them into patients as quickly as possible is something I've said is a real priority for us this term.' Because the PBS compels drugmakers to negotiate prices with the federal government, PhRMA has accused Australia of 'freeloading' on US-funded research and development. Meanwhile, American consumers pick up the bill, according to the lobby group. 'The medicines industry, understandably, given their interest, want to make prices higher as well, so there will be a bit of a debate about how we do that,' Mr Butler said. 'But I'm very much on the page of getting medicines more quickly into our system, our PBS system. 'It's a terrific system and we're trying to make medicines cheaper at the same time for Australians.' PhRMA has explicitly urged the Trump administration to 'leverage ongoing trade negotiations' to influence Australia's PBS policies. Mr Butler has echoed Anthony Albanese and fellow senior government ministers in ruling out any 'compromise' on the system as part of tariff talks. For the moment, Donald Trump's concern with the sector appears to be largely focused on bringing down prices in the US rather than punishing allies for having cheaper medicines. A RAND Corporation report found that Americans pay nearly four times more than Australians for medicines and about three times more than the average in other developed economies. The answer, according to the US President, is to make pharmaceuticals in the US. In a warning shot to firms, Mr Trump this week threatened to slap tariffs of up to 250 per cent on foreign-made products. With Australian pharma exports to the US worth more than $2bn in 2024, it would hit producers Down Under hard. Exports are mostly blood products and vaccines but also include packaged medicines and miscellaneous products, such as bandages. 'We'll be putting (an) initially small tariff on pharmaceuticals,' Mr Trump told US business news channel CNBC. 'In one year, 1½ years maximum, it's going to go to 150 per cent and then it's going to go to 250 per cent because we want pharmaceuticals made in our country.' He did not say what the initial rate would be, but earlier in the year he said duties on the sector would start from 25 per cent. Mr Trump last week wrote to 17 major pharmaceutical companies demanding they lower their prices for American consumers and bring them in line with prices overseas.
